104 results on '"Pochesci, A."'
Search Results
2. Inter-hospital cardiorespiratory telemonitoring of newborns and infants: a wellworking example of a hub and spoke network
3. A real‐life pediatric experience of Crohn's disease exclusion diet at disease onset and in refractory patients.
4. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC – The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
5. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
6. P919 Crohn’s Disease Exclusion Diet as add-on therapy in refractory pediatric patients
7. P680 A real-life experience of Crohn’s Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn’s disease
8. P680 A real-life experience of Crohn’s Disease Exclusion Diet use at disease onset and as an add-on therapy in pediatric Crohn’s disease
9. Fabrication and test of RF MEMS in LTCC technology
10. Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer
11. Inter-hospital cardiorespiratory telemonitoring of newborns and infants
12. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
13. Inter-hospital cardiorespiratory telemonitoring of newborns and infants.
14. LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: Results from the EORTC-ETOP NIVOTHYM phase II trial
15. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
16. Combined, patient-level, analysis of two randomised trials evaluating the addition of denosumab to standard first-line chemotherapy in advanced NSCLC - The ETOP/EORTC SPLENDOUR and AMGEN-249 trials
17. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy
18. REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
19. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
20. A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial
21. Minimally important differences for interpreting the EORTC QLQ-C30 in patients with advanced colorectal cancer treated with chemotherapy
22. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
23. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
24. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
25. Fabrication and test of RF MEMS in LTCC technology
26. LBA85 REACTION: A phase II study of etoposide and cis/carboplatin with or without pembrolizumab in untreated extensive small cell lung cancer
27. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
28. EORTC Lung Cancer Group survey on the definition of NSCLC synchronous oligometastatic disease
29. 9P Circulating tumour cells (CTCs) count and PD-L1 expression in untreated extensive small cell lung cancer patients treated in the REACTION trial, a phase II study of etoposide and cis/carboplatin with or without pembrolizumab (NCT02580994)
30. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
31. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
32. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
33. MA08.02 Durvalumab Impact in the Treatment Strategy of Stage III Non-Small Cell Lung Cancer (NSCLC): An EORTC Young Investigator Lung Cancer Group Survey
34. P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
35. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
36. The University Museum in Times of Fiscal Uncertainty: Fisk University and the Alfred Stieglitz Collection of Modern Art
37. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment
38. P1.06-06 EORTC 1205: Randomized Study of Pleurectomy/Decortication (P/D) Preceded or Followed by Chemotherapy in Malignant Pleural Mesothelioma
39. Lung Tissue Injury as an Atypical Response to Nivolumab in Non–Small Cell Lung Cancer
40. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
41. RF MEMS fabrication in LTCC technology
42. [Immunotherapy in non-small cell lung cancer: evolution of knowledge and clinical advances]
43. Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?
44. Abstract 2635: Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line
45. P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
46. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients
47. Personalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practice
48. Abstract 2635: Baseline myeloid-derived suppressor cell and eosinophil cell counts predict clinical efficacy in patients with non-small cell lung cancer (NSCLC) treated with nivolumab in second line
49. P2.01-044 Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second-Line Setting
50. Afatinib for the first-line treatment of patients with metastatic EGFR-positive NSCLC: a look at the data
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.